Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Vical's Allovectin-7 enters phase II for head and neck cancer

Sep. 8, 1997

TNT nears clinical trials

Sep. 2, 1997

FDA requests additional manufacturing data before approval of Rituxan

Sep. 1, 1997

Dovetail issued patent for Betathine

Aug. 28, 1997

Malignant melanoma indication approved for Intron A in U.K.

Aug. 27, 1997

Theratope vaccine advances to phase III trials

Aug. 21, 1997

Novopharm Biotech antibodies poised to enter phase I

Aug. 19, 1997

NeoRx and Janssen enter agreement for Avicidin

Aug. 14, 1997

ImClone Systems earns manufacturing milestone from Merck KGaA

Aug. 4, 1997

GnRH conjugate vaccines prepared at Merck & Co.

July 30, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...